In a decisive regulatory move aimed at curbing the proliferation of high-potency, synthetic psychoactive substances, the U.S. Drug Enforcement Administration…
Read More
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
Roche has solidified its strategic pivot toward the Chinese biotechnology sector by entering into a landmark $400 million partnership with…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
In a decisive move to address the burgeoning public health risks associated with the proliferation of synthetic, highly potent derivatives…
Read More
AI-Driven Oncology Pioneer Iambic Therapeutics Targets $135m Nasdaq IPO in Banner Year for Biotech Listings
Iambic Therapeutics, an oncology-focused biotechnology company recognized for its pioneering intersection of artificial intelligence and drug discovery, has officially set…
Read MoreDEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
The United States Drug Enforcement Administration (DEA) has initiated a significant regulatory crackdown on a burgeoning class of semi-synthetic alkaloids…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
The United States Drug Enforcement Administration (DEA) has initiated a significant regulatory crackdown on a burgeoning class of synthetic alkaloids…
Read More
Novo Unveils Post-Wegovy Growth Roadmap as Shares Slide Despite Ambitious 2030 Targets
The pharmaceutical landscape is undergoing a profound transformation, and Danish drugmaking giant Novo is aggressively positioning itself for a future…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
The United States Drug Enforcement Administration (DEA) has officially moved to curtail the proliferation of highly potent, synthetic derivatives associated…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
In a significant move to address the rising proliferation of potent, lab-engineered substances, the U.S. Drug Enforcement Administration (DEA) has…
Read More
Scientists Uncover How Gene Fusion Droplets Drive Rare Kidney Cancer Progression and Potential New Therapeutic Targets
In a significant breakthrough for oncology and molecular biology, a multidisciplinary team of investigators at the Johns Hopkins Kimmel Cancer…
Read More
